Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03731091 · ClinicalTrials.gov registry record · Phase 3
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
A Phase 3 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 3
- Development phase
- 494
- Enrollment target
NCT03731091 is a Phase 3 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 494 participants.
The verdict
NCT03731091, a Phase 3 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 494 participants
- Enrollment target
Study Summary
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)
Interventions
- DRUG Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
- DRUG Enstilar® foam (LEO Pharma Inc.)
- OTHER Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2020-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03731091
The ClinicalTrials.gov registry entry for NCT03731091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenmark Pharmaceuticals Ltd. India, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% is the first listed.
NCT03731091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03731091 about?
NCT03731091 is a clinical study titled "To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).". A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Phar...
What is the current status of trial NCT03731091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 494 participants. The study started on 2018-10-31. Estimated completion is 2020-03-17.
What interventions are being tested in trial NCT03731091?
The interventions under investigation include: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% (DRUG), Enstilar® foam (LEO Pharma Inc.) (DRUG), Placebo of Calcipotriene/ betamethasone dipropionate topical foam (OTHER).
Who is sponsoring clinical trial NCT03731091?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.